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Angiotensin II inhibits interleukin-1b–induced nitric oxide (NOS-III) are constitutively expressed, and their activi-
production in cultured rat mesangial cells. ties are mainly regulated by the Ca21/calmodulin system
Background. Macrophage-type nitric oxide synthase (NOS- [1]. In the kidney, NO derived from NOS-I and NOS-II) is expressed in glomerular mesangial cells in response to
III is involved in the regulation of glomerular hemody-inflammatory cytokines. Nitric oxide (NO) has antithrombotic
and cytostatic activities in glomerular diseases. Recent studies namics, water–electrolyte balance, and renin production
have suggested that several vasoactive substances and growth [2–7]. The third isoform of NOS, the macrophage-type
factors modulate NO production in a tissue-specific manner. NOS (NOS-II), is normally undetectable in renal tissue.The aim of this study was to examine whether angiotensin II
NOS-II is induced by the stimulation of inflammatoryand transforming growth factor-b (TGF-b) modulate cytokine-
stimulated NO production and NOS-II gene expression in rat cytokines such as interleukin-1b (IL-1b), tumor necrosis
glomerular mesangial cells. factor-a, and interferon-g (INF-g) in mesangial cells.
Methods. Cultured rat mesangial cells were incubated with Once induced, NOS-II is active for a prolonged periodinterleukin-1b (IL-1b) for 24 hours. The effects of angiotensin
and produces large amounts of NO. In experimentalII and TGF-b on stimulated nitrite accumulation and NOS-II
glomerulonephritis, NO has been demonstrated to pre-mRNA levels were determined.
Results. Angiotensin II and TGF-b significantly decreased vent glomerular thrombosis and ischemia [8–10]. Fur-
IL-1b–stimulated nitrite accumulation. The angiotensin type 1 thermore, NO attenuates mesangial cell proliferation
receptor antagonist CV11974 prevented angiotensin II-medi-
and extracellular matrix protein synthesis [11].ated inhibition of NO production. TGF-b–neutralizing anti-
Recent studies have demonstrated that angiotensinbody reversed the effect of TGF-b without affecting angioten-
sin II-mediated inhibition of NO production. TGF-b markedly II inhibits NOS-II–derived NO production in vascular
decreased steady-state levels of NOS-II mRNA and the half- smooth muscle cells and astroglial cells [12, 13]. Cur-
life of the message, whereas angiotensin II did not alter these rently, however, little is known about how this peptideparameters.
modulates NO formation in mesangial cells. AngiotensinConclusions. These results suggest that in mesangial cells,
angiotensin II and TGF-b participate in the inhibitory regula- II plays an important role in the progression of glomeru-
tion of cytokine-induced NO production. TGF-b inhibits NO lar diseases. It stimulates extracellular matrix protein
production by decreasing NOS-II mRNA levels, whereas angio- synthesis and mesangial proliferation, thereby opposing
tensin II may regulate NO production at the levels after NOS-II
the effects of NO in the glomerulus. The clinical rele-gene expression. An autocrine action of TGF-b induced by an-
vance of the renal angiotensin system has been impli-giotensin II is unlikely to contribute to angiotensin II-mediated
inhibition of NO production. cated by the beneficial effects of angiotensin-converting
enzyme inhibitors on various types of glomerular dis-
eases, such as glomerulonephritis, nephrosclerosis, and
The biosynthesis of nitric oxide (NO) is catalyzed by diabetic nephropathy [14–16]. Angiotensin II exhibits
three isoforms of nitric oxide synthase (NOS). The neu- these actions at least partly through an induction of trans-
roneal-type NOS (NOS-I) and endothelial-type NOS forming growth factor-b (TGF-b) in mesangial cells [17–
19]. It is therefore speculated that an inhibition of NO
production might be one of the mechanisms by whichKey words: NOS-II, TGF-b, inflammation, cytokines, gene expression,
glomerular thrombosis, progression of renal disease. angiotensin II accelerates glomerular diseases. The aim
of this study was to investigate how angiotensin II modu-
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METHODS were then incubated in the test medium containing IL-
1b with or without the test compounds for 24 hours.Materials
RPMI 1640 medium, fetal bovine serum, trypsin, and Nitrite analysis
ITS-Supplementt were purchased from GIBCO BRL The levels of nitrite, a stable metabolite of NO, in the
(Gaithersburg, MD, USA). Recombinant human IL-1b, medium were used as an index of NO production [20–23].
IL-6, and INF-g derived from E. coli were from Fujisawa- The medium was mixed with an equal volume of Griess
Pharmingen (Tokyo, Japan). Recombinant human TGF- reagent containing 1% sulfanilamide, 0.1% naphthyleth-
b1 derived from CHO cells and chicken anti–TGF-b IgY ylenediamine dihydrochloride, and 2% phosphoric acid
antibody were purchased from R&D Systems (Minneap- for 10 minutes. The absorbance at 540 nm was measured
olis, MN, USA). Other chemicals were obtained from triplicate with a 96-well plate reader (Immunoreader;
Sigma Chemical (St. Louis, MO, USA). Intermed, Tokyo, Japan), and the nitrite concentration
The ED50, as determined by the dose-dependent stimu- was determined using a calibration curve with sodium
lation of thymidine uptake by mouse C3H/HeJ thymo- nitrite standards.
cytes, and the specific activity of IL-1b were 0.1 ng/ml
Isolation of RNA and Northern blot analysisand 107 U/mg, respectively. The ED50 and the specific
activity of IL-6 were 0.1 ng/ml and 107 U/mg, respectively. The levels of NOS-II mRNA were determined by
The ED50, as determined by the dose-dependent induc- Northern blot analysis, as described previously [4, 5, 7].
tion of resistance to vesicular stomatitis virus by WISH Mesangial cells were washed twice with ice-cold 10 mm
cells, and the specific activity of INF-g were 0.15 ng/ml phosphate-buffered saline (pH 7.4), and total RNA was
and 6.7 3 106 U/mg, respectively. The ED50 of TGF-b, as extracted by acid guanidinium thiocyanate-phenol-chlo-
roform method [24]. Twenty micrograms of RNA weredetermined by the inhibition of the murine IL-4–depen-
loaded on 1% agarose gel, size fractionated, and trans-dent thymidine incorporation by HT-2 cells, was 0.02 to
ferred to nylon membrane filters (Gene Screen Plus;0.06 ng/ml. Anti–TGF-b antibody purified from egg yolk
DuPont-NEN, Boston, MA, USA). The membraneswas specific for neutralizing the biologic activity of re-
were hybridized with 32P-random-labeled rat NOS-IIcombinant human TGF-b1. This antibody showed less
cDNA probe (106 cpm/ml) [25] for 24 hours at 608C. Thethan 10% cross-reactivity with TGF-b5, less than 2%
membranes were then washed twice with 2 3 standardcross-reactivity with TGF-b2 and TGF-b3, and no cross-
saline citrate (SSC) containing 1% sodium dodecyl sul-reactivity with other cytokines. The ND50 of anti–TGF-b
fate (SDS) for 30 minutes at 608C and twice with 0.1 3antibody, as defined by the concentration required to
SSC for 15 minutes at room temperature. Radioactiveyield one half of the maximal inhibition of the activity
signals of the hybridized membranes were analyzed usingof a supramaximal concentration (0.25 ng/ml) of recom-
a bioimaging analyzer FUJIX BAS-2000 (Fuji Film,binant human TGF-b1 on HT-2 cells, as described earlier
Tokyo, Japan). The NOS-II probe was stripped withhere, was 0.2 to 0.6 mg/ml.
boiling 0.1 3 SSC/1% SDS, and the membranes were
rehybridized with a 32P-labeled 18S ribosomal RNA probe.Mesangial cell culture
Kidneys were removed from male Sprague-Dawley Statistical analysis
rats weighing 150 to 200 g, and the cortex was dissected.
Data are expressed as means 6 se, and statistical sig-
The glomeruli were isolated from minced cortex by pass-
nificance was determined by unpaired t-test, linear re-
ing through 250, 149, and 53 mm mesh sieves. Mesangial gression analysis, or analysis of covariance. P values less
cells were cultured from isolated glomeruli after the than 0.01 were considered statistically significant.
treatment of 0.25% trypsin and 0.02% ethylenediamine-
tetraacetic acid (EDTA). Cells were grown in RPMI
RESULTS1640 medium containing 20% fetal bovine serum, 100
U/ml penicillin, 100 mg/ml streptomycin, and ITS-Supple- Nitric oxide formation and NOS-II gene expression
mentt at 378C in 5% CO2 and 95% air. The outgrowing stimulated by interleukin-1b
cells were identified as mesangial cells by spindle-shaped As shown in Figure 1, the incubation of cultured mes-
morphology, positive immunohistochemical staining for angial cells with IL-1b for 24 hours resulted in dose-
rat Thy-1.1 antigen, smooth muscle cell actin, desmin, dependent increases in NO production and NOS-II gene
and vimentin and were negative for factor VIII. The cells expression. The highest dose (100 U/ml) of IL-1b pro-
were studied between passages 3 and 5. Confluent mesan- duced approximately sixfold increases in the levels of
gial cells were incubated in phenol red-free test medium nitrite and NOS-II mRNA. In our experiments, other
supplemented with 0.1% bovine serum albumin and ITS- cytokines did not influence NO formation or NOS-II
gene expression (Table 1).Supplementt for 48 hours before the experiments. They
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Fig. 1. Dose-dependent increase in nitrite accumulation (A) and nitric oxide synthase (NOS)-II mRNA expression (B) stimulated by interleukin
(IL)-1b in cultured rat mesangial cells. Values are expressed as means 6 sem from four experiments. *P , 0.01 vs. nonstimulated control.
Table 1. Effect of cytokines on nitrite concentrations in the NOS-II gene expression, Northern blot analysis was per-
medium in cultured rat mesangial cells
formed. As shown in Figure 2B, angiotensin II or CV11974
Treatment N Nitrite levels lm did not significantly influence NOS-II mRNA levels
Vehicle 8 5.560.1
IL-1b 100 U/ml 4 33.4 60.85a Effect of transforming growth factor-b and
IL-6 100 U/ml 4 5.8 60.1b anti-transforming growth factor-b antibody
INF-g 100 U/ml 4 5.6 60.1b
on nitric oxide formationIL-1b 100 U/ml 1 IL-6 100 U/ml 4 34.2 61.2a
IL-1b 100 U/ml 1 INF-g 100 U/ml 4 36.1 62.5a Transforming growth factor-b inhibited IL-1b–stimu-
Values are means 6 sem. Abbreviations are: IL, interleukin; INF, interferon. lated NO production and NOS-II gene expression in a
a P , 0.01 vs. vehicle-treated control
dose-dependent manner (Fig. 3). When 5 ng/ml of TGF-bb P , 0.01 vs. IL-1b alone
was applied, the mean nitrite concentration and the
NOS-II mRNA level were decreased by 80% and 60%,
respectively. This inhibitory effect of TGF-b was abol-
Effect of angiotensin II on interleukin-1b–stimulated ished by TGF-b–neutralizing antibody. The treatment
nitric oxide formation of this antibody alone did not affect NO production or
When mesangial cells were coincubated with angioten- NOS-II gene expression.
sin II, IL-1b–stimulated nitrite levels were significantly It has been suggested that angiotensin II induces TGF-b
decreased (Fig. 2A). The highest concentration (1026 m) secretion from mesangial cells. To examine whether the
of angiotensin II reduced the mean nitrite level by ap- inhibitory effect of angiotensin II on NO production was
proximately 40%. This angiotensin II-mediated inhibi- mediated by an autocrine action of TGF-b, IL-1b–stimu-
tion of NO production was prevented by 1025 m of the lated mesangial cells were coincubated with angiotensin II
angiotensin type 1 (AT1) receptor antagonist CV11974 and TGF-b–neutralizing antibody. As shown in Figure 4,
(Fig. 2A), whereas the same concentration of PD123319, this antibody did not reverse the effect of angiotensin II.
an angiotensin type 2 (AT2) receptor antagonist, did
Effect of angiotensin II and transforming growthnot alter the effect of angiotensin II (data not shown).
factor-b on the stability of NOS-II geneCV11974 alone did not affect NO formation.
To examine whether angiotensin II-mediated inhibi- After the stimulation of IL-1b (100 U/ml) for 24 hours,
mesangial cells were treated with vehicle, angiotensin II,tion of NO production was associated with changes in
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Fig. 2. Effect of angiotensin II on interleukin (IL)-1b–stimulated nitric oxide (NO) formation (A) and nitric oxide synthase (NOS)-II mRNA
levels (B). Glomerular mesangial cells were stimulated with 100 U/ml IL-1b in the presence of test medium or its vehicle. Values are expressed
as means 6 sem from six to eight experiments. *P , 0.01 vs. vehicle-treated control.
or TGF-b under the presence of 5 mg/ml of actinomycin myocytes [23]. This study demonstrated that in mesangial
cells, angiotensin II and TGF-b significantly decreasedD. NOS-II mRNA levels divided by 18S rRNA levels
were determined at one, two, four, and eight hours (Fig. IL-1b–stimulated NO formation. This angiotensin II-
mediated inhibition of NO production was reversed by5). The half-life of NOS-II mRNA was approximately
2.3 hours in the vehicle-treated group. Angiotensin II CV11974, thereby indicating that the AT1 receptor is
responsible for the effect of angiotensin II. The localdid not alter the half-life of NOS-II mRNA, whereas
TGF-b significantly reduced it to approximately 1.5 levels of angiotensin II in the glomerular space may be
sufficient to affect NO release in vivo [28]. The inhibitoryhours. An analysis of covariance indicated the probabil-
effect of TGF-b on NO production is consistent with theity that the slopes from vehicle– and TGF-b–treated
results of an earlier study [29]. These results suggest thatgroups were the same at less than 0.01.
angiotensin II and TGF-b negatively regulate cytokine-
stimulated NO production in mesangial cells.
DISCUSSION Because angiotensin II induces secretion of TGF-b
In glomerulonephritis, inflammatory cytokines are se- from mesangial cells [18, 19], it could be argued that the
creted locally in glomeruli and affect mesangial cell func- inhibitory effect of angiotensin II on NO production was
tions [26, 27]. As demonstrated in this study, mesangial mediated through TGF-b secretion. As demonstrated
cells express NOS-II gene and produce large amounts in this study, TGF-b is a potent inhibitor of NOS-II
of NO in response to IL-1b. It has been demonstrated expression. TGF-b–neutralizing antibody, however, did
that NOS-II–derived NO is regulated by several of vaso- not alter the effect of angiotensin II. This antibody com-
constrictors and cell growth factors. Angiotensin II and pletely reversed TGF-b–mediated inhibition of NO pro-
TGF-b are known to inhibit cytokine-induced NO pro- duction. Therefore, an autocrine action of TGF-b on
duction in vascular smooth muscle cells, macrophages, mesangial cells is unlikely to contribute to the effect of
and astroglial cells [12, 13, 20–22]. In contrast, angioten- angiotensin II.
Angiotensin II and TGF-b have been implicated insin II was shown to augment NO synthesis in cardiac
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Fig. 3. Effect of transforming growth factor-b (TGF-b) and TGF-b–neutralizing antibody (a-TGF-b, anti–TGF-b antibody) experiments on
interleukin (IL)-1b–stimulated nitric oxide (NO) formation (A) and NOS-II mRNA levels (B). Mesangial cells were stimulated with 100 U/ml
IL-1b in the presence of the test medium or its vehicle. Values are expressed as means 6 sem from four experiments. *P , 0.01 vs. vehicle-treated
control.
during the course of glomerulonephritis [8–10]. In cul-
tured mesangial cells, NO inhibits mesangial prolifera-
tion and extracellular matrix protein synthesis [11]. The
results of this study suggest that decreased NO produc-
tion might be one of the mechanisms by which angioten-
sin II and TGF-b accelerate glomerular injury. Selective
modulation of this mechanism will find potential applica-
tions in therapy in glomerular diseases.
In our study, angiotensin II failed to affect NOS-II
mRNA levels in mesangial cells, whereas TGF-b mark-
edly reduced them. Earlier studies have demonstrated
that angiotensin II and TGF-b regulate NOS-II gene
expression in a tissue-specific manner. In vascular smooth
muscle cells and astroglial cells, angiotensin II decreases
NO production by inhibiting NOS-II gene expression
Fig. 4. Effect of anti-TGF-b antibody (a-TGF-b) on angiotensin II- [12, 13]. On the other hand, in the renal tubular cells,
mediated inhibition of interleukin (IL)-1b-stimulated nitric oxide (NO) angiotensin II suppresses INF-g–stimulated NO forma-formation. Mesangial cells were stimulated with 100 U/ml IL-1b in the
tion without affecting gene transcription or steady-statepresence of test medium or its vehicle. Values are expressed as means 6
sem from four experiments. *P , 0.01 vs. vehicle-treated control. levels of NOS-II mRNA [31]. TGF-b was shown to de-
crease NO production in macrophages by three distinct
mechanisms, including decreased stability and transla-
tion of NOS-II mRNA and increased degradation ofthe progression of glomerular diseases by stimulating
NOS-II protein [20]. Although TGF-b decreases stimu-mesangial cell growth and extracellular matrix protein
lated NO production in vascular smooth muscle cells, itsynthesis [19, 30]. In addition, angiotensin II is a major
remains controversial how TGF-b regulates NOS-II genecause of glomerular hypertension, thereby promoting
expression [21, 22]. In our study, in glomerular mesangialglomerulosclerosis [14–16]. In contrast, NO has been
shown to prevent glomerular thrombosis and ischemia cells, NOS-II mRNA levels and the half-life of the mes-
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